ATRA functions by binding to retinoic acid receptors (RARs) in the cell nucleus. This binding leads to changes in gene expression, which can induce differentiation and inhibit the proliferation of malignant cells. In APL, ATRA promotes the maturation of abnormal promyelocytes into normal white blood cells, effectively reducing the leukemic cell burden.
